• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

眼压降低与角膜肿胀：奈他地尔治疗引发的意外角膜水肿

Drop and Swell: Unanticipated Corneal Edema From Netarsudil Therapy.

作者信息

Kamdar Gufran A, Chodvadiya Surbhi A, Paranjpe Radhika

机构信息

Ophthalmology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, IND.

出版信息

Cureus. 2024 Nov 10;16(11):e73376. doi: 10.7759/cureus.73376. eCollection 2024 Nov.

DOI:10.7759/cureus.73376
PMID:39659328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11631165/
Abstract

Neovascular glaucoma (NVG) poses significant treatment challenges, often necessitating complex medication regimens to manage intraocular pressure (IOP). This report details a 65-year-old male with NVG secondary to central retinal artery occlusion (CRAO), who developed corneal epithelial bullae as a rare side effect of topical netarsudil therapy. Despite this complication, a continued treatment led to the gradual resolution of corneal lesions while maintaining controlled IOP. This case underscores the importance of vigilant monitoring for adverse effects and highlights the need for further research into netarsudil's safety profile in NVG management.

摘要

新生血管性青光眼（NVG）带来了重大的治疗挑战，通常需要复杂的药物治疗方案来控制眼压（IOP）。本报告详细介绍了一名65岁男性，患有继发于视网膜中央动脉阻塞（CRAO）的NVG，他出现了角膜上皮大疱，这是局部使用奈他地尔治疗罕见的副作用。尽管出现了这种并发症，但持续治疗导致角膜病变逐渐消退，同时眼压保持在可控范围内。该病例强调了警惕监测不良反应的重要性，并突出了对奈他地尔在NVG治疗中的安全性进行进一步研究的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1066/11631165/5b7c9088836c/cureus-0016-00000073376-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1066/11631165/89c28cabf22f/cureus-0016-00000073376-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1066/11631165/8ff0d0c2bdce/cureus-0016-00000073376-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1066/11631165/5b7c9088836c/cureus-0016-00000073376-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1066/11631165/89c28cabf22f/cureus-0016-00000073376-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1066/11631165/8ff0d0c2bdce/cureus-0016-00000073376-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1066/11631165/5b7c9088836c/cureus-0016-00000073376-i03.jpg

相似文献

1
Drop and Swell: Unanticipated Corneal Edema From Netarsudil Therapy.眼压降低与角膜肿胀：奈他地尔治疗引发的意外角膜水肿
Cureus. 2024 Nov 10;16(11):e73376. doi: 10.7759/cureus.73376. eCollection 2024 Nov.
2
A review of neovascular glaucoma. Etiopathogenesis and treatment.新生血管性青光眼的综述。病因发病机制与治疗。
Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329. doi: 10.22336/rjo.2021.66.
3
Central retinal artery occlusion without underlying chronic ocular ischemic syndrome may lead to neovascular glaucoma.无潜在慢性眼部缺血综合征的视网膜中央动脉阻塞可能导致新生血管性青光眼。
J Fr Ophtalmol. 2017 Nov;40(9):758-762. doi: 10.1016/j.jfo.2017.05.005. Epub 2017 Oct 19.
4
Rapid Onset Neovascular Glaucoma due to COVID-19-related Retinopathy.由COVID-19相关视网膜病变引起的快速进展性新生血管性青光眼
J Curr Glaucoma Pract. 2022 May-Aug;16(2):136-140. doi: 10.5005/jp-journals-10078-1356.
5
A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma.奈他地尔治疗高眼压症和开角型青光眼24小时疗效及耐受性的随机2期研究
Ophthalmol Ther. 2021 Mar;10(1):89-100. doi: 10.1007/s40123-020-00322-1. Epub 2020 Nov 26.
6
Effectiveness of Netarsudil versus Brimonidine in Eyes already Being Treated with Glaucoma Medications at a Single Academic Tertiary Care Practice: A Comparative Study.在单一学术三级医疗中心，已使用青光眼药物治疗的眼中，奈他地尔与溴莫尼定的疗效比较研究
Curr Ther Res Clin Exp. 2022 Nov 24;98:100689. doi: 10.1016/j.curtheres.2022.100689. eCollection 2023.
7
Iris Thickness and Severity of Neovascular Glaucoma Determined Using Swept-Source Anterior-segment Optical Coherence Tomography.应用扫频源眼前节光学相干断层扫描仪测量虹膜厚度和新生血管性青光眼的严重程度。
J Glaucoma. 2018 May;27(5):415-420. doi: 10.1097/IJG.0000000000000921.
8
Anti-vascular endothelial growth factor for neovascular glaucoma.抗血管内皮生长因子治疗新生血管性青光眼。
Cochrane Database Syst Rev. 2023 Apr 3;4(4):CD007920. doi: 10.1002/14651858.CD007920.pub4.
9
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.玻璃体内注射贝伐单抗治疗41例连续性缺血性视网膜疾病继发的虹膜新生血管和新生血管性青光眼。
Ophthalmology. 2008 Sep;115(9):1571-80, 1580.e1-3. doi: 10.1016/j.ophtha.2008.02.026. Epub 2008 Apr 28.
10
A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial.一项前瞻性、随机、安慰剂对照、双盲、三臂、多中心II/III期试验，用于研究缺血性视网膜中央静脉阻塞的局部治疗以预防新生血管性青光眼——STRONG研究：一项随机对照试验的研究方案
Trials. 2017 Mar 16;18(1):128. doi: 10.1186/s13063-017-1861-3.

本文引用的文献

1
Reticular corneal epithelial edema with topical netarsudil.使用局部拉坦前列素后出现网状角膜上皮水肿。 （注：你原文中的“netarsudil”有误，推测你想表达的是“netarsoprost”，这里按照正确药物名翻译了，若不是，请根据实际情况调整）
Oman J Ophthalmol. 2023 Feb 21;16(1):94-97. doi: 10.4103/ojo.ojo_2_22. eCollection 2023 Jan-Apr.
2
Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario.Rho 激酶抑制剂的一种新的眼部副作用：网状细胞角膜上皮水肿——印度情况。
Indian J Ophthalmol. 2022 Apr;70(4):1163-1170. doi: 10.4103/ijo.IJO_2865_21.
3
Netarsudil-associated reticular corneal epithelial edema.
奈他地尔相关性网状角膜上皮水肿。
Am J Ophthalmol Case Rep. 2022 Jan 20;25:101287. doi: 10.1016/j.ajoc.2022.101287. eCollection 2022 Mar.
4
Rhopressa-induced corneal edema: a case report.罗普雷斯诱导的角膜水肿：一例报告。
J Med Case Rep. 2021 Apr 2;15(1):182. doi: 10.1186/s13256-021-02665-0.
5
Netarsudil-associated epithelial keratopathy.奈他地尔相关性上皮性角膜病变。
Am J Ophthalmol Case Rep. 2020 Jun 28;19:100800. doi: 10.1016/j.ajoc.2020.100800. eCollection 2020 Sep.
6
Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series.网状疱状上皮水肿在奈立定治疗角膜中的病例系列。
Am J Ophthalmol. 2020 Sep;217:20-26. doi: 10.1016/j.ajo.2020.04.002. Epub 2020 Apr 11.
7
Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.每日一次的奈塔沙尔与每日两次的噻吗洛尔治疗高眼压症患者的比较：随机 3 期 ROCKET-4 研究。
Am J Ophthalmol. 2019 Aug;204:97-104. doi: 10.1016/j.ajo.2019.03.002. Epub 2019 Mar 9.
8
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).两项比较奈立定（netarsudil）和噻吗洛尔（timolol）安全性和疗效的 3 期临床试验： Rho 激酶升高的眼压治疗试验 1 和 2（ROCKET-1 和 ROCKET-2）。
Am J Ophthalmol. 2018 Feb;186:116-127. doi: 10.1016/j.ajo.2017.11.019. Epub 2017 Dec 1.